TNFRSF8 and mature T-cell and NK-cell non-Hodgkin lymphoma: NCCN Guidelines recommend brentuximab vedotin plus CHP as a preferred first-line therapy option for ALCL (category 1) or other CD30-positive entities including PTCL-NOS (category 2A).